天境生物美股招股说明书(2025-07-11版)

We are no longer subject to the General Instruction I.B.5 ofFormF-3as the aggregate market value of our ordinary shares (including ordinaryshares represented by ADSs) held bynon-affiliatesequaled or exceeded $75.0million as of June9, 2025. Accordingly, we are filing this Amendment toupdate the maximum amount of ADSs that we are eligible to sell under the Prospectus. Following this Amendment, we may offer and sell ADSs having an aggregate offering price of up to $50,000,000 pursuant to this Amendment and the Prospectus in accordance with the terms of the Sales Agreement.Our ADSs are currently listed on the Nasdaq Global Market (“Nasdaq”) under the symbol “IMAB”. On July10, 2025, the last reported sales priceof the ADSs on Nasdaq was $2.05 per ADS. this Amendment and the Prospectus.NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVEDOR DISAPPROVED OF THESE SECURITIES OR PASSED UPON THE ADEQUACY OR ACCURACY OF THIS PROSPECTUS Leerink Partners